EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Codexis's enterprise value is $143.54 Mil.
Codexis's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $70.14 Mil. Therefore, Codexis's EV-to-Revenue for today is 2.05.
The historical rank and industry rank for Codexis's EV-to-Revenue or its related term are showing as below:
CDXS'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.52 Med: 3.86 Max: 25.92
Current: 2.05
During the past 13 years, the highest EV-to-Revenue of Codexis was 25.92. The lowest was 0.52. And the median was 3.86.
CDXS's EV-to-Revenue is ranked better than 78.39% of 1032
companies
in the Biotechnology industry
Industry Median: 7.615
vs CDXS: 2.05
As of today (2024-04-18), Codexis's stock price is $2.76.
Codexis's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.03. Therefore, Codexis's PS Ratio for today is 2.68.
Codexis EV-to-Revenue Historical Data
The historical data trend for Codexis's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Codexis Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-Revenue
12.81
18.51
18.78
1.71
2.34
Codexis Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-Revenue
1.71
1.86
1.46
1.05
2.34
Competitive Comparison
For the Biotechnology subindustry, Codexis's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Codexis EV-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, Codexis's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Codexis's EV-to-Revenue falls into.
Codexis's current Enterprise Value is $143.54 Mil.
Codexis's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $70.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Codexis's share price for today is $2.76.
Codexis's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Codexis EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Codexis's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases, etc. The company operates in two business segments namely Performance Enzymes and Novel Biotherapeutics. It generates maximum revenue from the Performance Enzymes segment. Geographically, it derives a majority of revenue from the APAC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CDXS has been successfully added to your 